HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
C12orf57
chromosome 12 open reading frame 57
Chromosome 12 Β· 12p13.31
NCBI Gene: 113246Ensembl: ENSG00000111678.11HGNC: HGNC:29521UniProt: F5GXW5
37PubMed Papers
21Diseases
0Drugs
22Pathogenic Variants
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingpost-embryonic developmentregulation of skeletal muscle contractioncorpus callosum morphogenesistemtamy syndromeAicardi-Goutieres syndrome 9SpasticityGlobal developmental delay
✦AI Summary

C12ORF57 is a conserved protein essential for neuronal development and synaptic homeostasis, primarily characterized by its role in corpus callosum morphogenesis and excitatory neuronal regulation. 1 Loss-of-function mutations in C12ORF57 cause Temtamy syndrome, an autosomal recessive neurodevelopmental disorder characterized by intellectual disability, epilepsy, and corpus callosum dysgenesis. 2 The syndrome presents with variable phenotypic expressivity; among 56 patients, 73.2% exhibited epilepsy, 63% had corpus callosal abnormalities, and additional features included congenital heart disease (51.4%) and white matter abnormalities (38%). 2 Mechanistically, C12ORF57 (also termed GRCC10) functions as a principal regulator of synaptic AMPA receptor homeostatic downscaling in response to elevated neuronal activity. 3 The protein modulates calcium/calmodulin-dependent kinase 4 (CAMK4) activity, thereby regulating CREB and ARC expression to control AMPA receptor levels. 3 Loss of C12ORF57 function disrupts this homeostatic mechanism, resulting in elevated AMPA receptor expression and increased miniature excitatory postsynaptic current amplitudes, leading to enhanced seizure susceptibility. 3 C12ORF57 variants should be considered in developmental delay/intellectual disability etiology, particularly in consanguineous populations where founder mutations exist. 2

Sources cited
1
C12ORF57 loss-of-function mutations cause Temtamy syndrome with variable phenotypic features including intellectual disability (100%), epilepsy (73.2%), corpus callosal abnormalities (63%), congenital heart disease (51.4%), and white matter abnormalities (38%)
PMID: 29383837
2
Compound heterozygous mutations in C12ORF57 cause intellectual disability with corpus callosum hypoplasia, chorioretinal coloboma, and intractable seizures
PMID: 24798461
3
C12ORF57/GRCC10 is a principal regulator of synaptic AMPA receptor homeostatic downscaling, modulates CAMK4 activity and CREB/ARC expression; loss of function increases AMPA receptor expression and seizure susceptibility
PMID: 39974932
4
C12ORF57 is required for corpus callosum development; mutations at the initiator methionine codon cause recessive corpus callosum hypoplasia
PMID: 23453666
5
Novel compound heterozygous C12ORF57 variants cause Temtamy syndrome with overlapping phenotypic features of developmental delay, autism, and corpus callosal dysgenesis
PMID: 37451886
6
C12ORF57 variants including start loss and stop gain mutations cause developmental and epileptic encephalopathy
PMID: 35791610
7
C12ORF57 mutations are associated with microphthalmia, anophthalmia, and coloboma phenotypes
PMID: 24859618
Disease Associationsβ“˜21
temtamy syndromeOpen Targets
0.80Strong
Aicardi-Goutieres syndrome 9Open Targets
0.51Moderate
SpasticityOpen Targets
0.41Moderate
Global developmental delayOpen Targets
0.40Weak
neurodegenerative diseaseOpen Targets
0.34Weak
Intellectual disabilityOpen Targets
0.34Weak
attention deficit hyperactivity disorderOpen Targets
0.33Weak
hydronephrosisOpen Targets
0.33Weak
Renal atrophyOpen Targets
0.33Weak
vesicoureteral refluxOpen Targets
0.33Weak
Abnormal corpus callosum morphologyOpen Targets
0.26Weak
microphthalmia, isolated, with colobomaOpen Targets
0.26Weak
SeizureOpen Targets
0.26Weak
genetic disorderOpen Targets
0.18Weak
Autosomal dominant methemoglobinemiaOpen Targets
0.06Suggestive
diffuse palmoplantar keratoderma - acrocyanosis syndromeOpen Targets
0.06Suggestive
Diffuse palmoplantar keratoderma-acrocyanosis syndromeOpen Targets
0.06Suggestive
hemoglobin M diseaseOpen Targets
0.05Suggestive
cleft larynx, posteriorOpen Targets
0.04Suggestive
neoplasmOpen Targets
0.02Suggestive
Temtamy syndromeUniProt
Pathogenic Variants22
NM_138425.4(C12orf57):c.182del (p.Ile61fs)Pathogenic
Temtamy syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 61
NM_138425.4(C12orf57):c.2T>G (p.Met1Arg)Pathogenic
Temtamy syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 1
NM_138425.4(C12orf57):c.1A>G (p.Met1Val)Pathogenic
Temtamy syndrome|Global developmental delay;Abnormal corpus callosum morphology;Microphthalmia, isolated, with coloboma;Seizure|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 1
NM_138425.4(C12orf57):c.184C>T (p.Gln62Ter)Pathogenic
Temtamy syndrome|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 62
NM_138425.4(C12orf57):c.53-2A>GPathogenic
6 conditions|Temtamy syndrome
β˜…β˜…β˜†β˜†2024
NM_138425.4(C12orf57):c.43C>T (p.Gln15Ter)Pathogenic
not provided|Temtamy syndrome
β˜…β˜…β˜†β˜†2023β†’ Residue 15
NM_138425.4(C12orf57):c.52+1G>CLikely pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2025
NM_138425.4(C12orf57):c.145A>T (p.Lys49Ter)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 49
NM_138425.4(C12orf57):c.4del (p.Ala2fs)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 2
NM_138425.4(C12orf57):c.154C>T (p.Gln52Ter)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 52
NM_138425.4(C12orf57):c.286_287del (p.Ala96fs)Likely pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2023β†’ Residue 96
NM_138425.4(C12orf57):c.41dup (p.Gln15fs)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2022β†’ Residue 15
NM_138425.4(C12orf57):c.53-1G>ALikely pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2022
NM_138425.4(C12orf57):c.52+1G>TLikely pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2022
NM_138425.4(C12orf57):c.19C>T (p.Gln7Ter)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2022β†’ Residue 7
NM_138425.4(C12orf57):c.143del (p.Gly48fs)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2022β†’ Residue 48
NM_138425.4(C12orf57):c.53_54delPathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2021
NM_138425.4(C12orf57):c.55dup (p.Val19fs)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2021β†’ Residue 19
NM_138425.4(C12orf57):c.174del (p.Thr59fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2019β†’ Residue 59
NM_138425.4(C12orf57):c.161_162del (p.Val54fs)Pathogenic
Temtamy syndrome
β˜…β˜†β˜†β˜†2018β†’ Residue 54
View on ClinVar β†—
Related Genes
ANKRD50Protein interaction99%HLA-BProtein interaction81%PLAC8Protein interaction77%HLA-AProtein interaction77%LINS1Shared pathway25%JAKMIP1Shared pathway25%
Tissue Expression6 tissues
Ovary
100%
Brain
59%
Heart
43%
Liver
39%
Lung
38%
Bone Marrow
23%
Gene Interaction Network
Click a node to explore
C12orf57ANKRD50HLA-BPLAC8HLA-ALINS1JAKMIP1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q99622
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
1.73LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF1.14 [0.75–1.73]
RankingsWhere C12orf57 stands among ~20K protein-coding genes
  • #10,596of 20,598
    Most Researched37
  • #2,110of 5,498
    Most Pathogenic Variants22
  • #16,265of 17,882
    Most Constrained (LOEUF)1.73
Genes detectedC12orf57
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Further delineation of Temtamy syndrome of corpus callosum and ocular abnormalities.
PMID: 29383837
Am J Med Genet A Β· 2018
1.00
2
Exome sequencing identifies compound heterozygous mutations in C12orf57 in two siblings with severe intellectual disability, hypoplasia of the corpus callosum, chorioretinal coloboma, and intractable seizures.
PMID: 24798461
Am J Med Genet A Β· 2014
0.90
3
C12ORF57: a novel principal regulator of synaptic AMPA currents and excitatory neuronal homeostasis.
PMID: 39974932
bioRxiv Β· 2025
0.80
4
Identification of epilepsy concomitant candidate genes recognized in Saudi epileptic patients.
PMID: 35363364
Eur Rev Med Pharmacol Sci Β· 2022
0.70
5
The genetic architecture of microphthalmia, anophthalmia and coloboma.
PMID: 24859618
Eur J Med Genet Β· 2014
0.60